5/8/2025

We recently published a list of 10 Stocks with Insanely High PE Ratios Insiders Are Selling. In this article, we are going to take a look at where Innoviva, Inc. (NASDAQ:INVA) stands against other stocks with insanely high PE ratios insiders are selling. The U.S. stock market has turned into a theater of extremes right […]

Source: Yahoo

5/8/2025

BURLINGAME - Innoviva, Inc. , a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics , and a...

Source: Finnhub

5/7/2025

BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported a loss of $46.6 million in its first quarter.

Source: Yahoo

5/7/2025

BURLINGAME, Calif., May 07, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2025, and highlighted select corporate progress and achievements.

Source: Yahoo

4/11/2025

Source: SeekingAlpha

4/10/2025

With its stock down 4.2% over the past week, it is easy to disregard Innoviva (NASDAQ:INVA). It is possible that the...

Source: Yahoo

3/21/2025

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Source: Yahoo

3/14/2025

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Source: Yahoo

3/12/2025

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's

Source: Yahoo

3/5/2025

BURLINGAME, Calif., March 05, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on T

Source: Yahoo

2/28/2025

Innoviva ( NASDAQ:INVA ) Full Year 2024 Results Key Financial Results Revenue: US$358.7m (up 16% from FY 2023). Net...

Source: Yahoo

2/26/2025

BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported net income of $20.3 million in its fourth quarter.

Source: Yahoo

2/26/2025

BURLINGAME, Calif., February 26, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements.

Source: Yahoo

2/23/2025

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents an asymmetric risk-reward profile.

Source: SeekingAlpha